The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 5, 2021. Its latest SEC filing is a SC 13G/A from Apr 26, 2023.
10-Q for Q3 FY2021, filed Nov 5, 2021
The sections below describe the company as of the FY2020 annual report.
Provides managed behavioral and specialty health services, pharmacy benefit management, and pharmacy administration for health plans, employers, and government agencies.
10-K for FY2020, filed Feb 26, 2021The Behavioral & Specialty Health reporting unit’s customers include health plans, accountable care organizations (“ACOs”), employers, the…View ↗
The Pharmacy Management segment (“Pharmacy Management”) is comprised of services that provide clinical and financial management of…View ↗
These services are available individually, in combination, or in a fully integrated manner. The Company markets its pharmacy management…View ↗
Pharmacy benefit customers pay negotiated prescription prices, copayments and administrative fees when claims are processed or drugs ship. Managed healthcare brings in per-member monthly fees; government pharmacy administration also earns fixed monthly fees, while formulary programs retain administrative fees or a share of rebates.
10-K for FY2020, filed Feb 26, 2021Pharmacy Benefit Management Revenue. The Company’s customers for PBM business, including pharmaceutical dispensing operations, are…View ↗
Per Member Per Month (“PMPM”) Revenue. Almost all of the Healthcare revenue and a small portion of the Pharmacy Management revenue is paid…View ↗
Pharmacy Benefit Administration Revenue. The Company provides Medicaid pharmacy services to states and other government sponsored programs.…View ↗
Formulary Management Revenue. The Company administers formulary management programs for certain clients through which the Company…View ↗
10-K for FY2020, filed Feb 26, 2021
FY2020 revenue by product or service ↗$4.6B
10-K for FY2020, filed Feb 26, 2021
$4.6B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Behavioral & Specialty Health, risk-based, non-EAP
Recurring
10-K for FY2020, filed Feb 26, 2021 |
31% |
Behavioral & Specialty Health, risk-based, non-EAP, FY2020
$1.4B Sources
|
Recurring |
|
Behavioral & Specialty Health, EAP risk-based
Recurring
|
6.9% |
Behavioral & Specialty Health, EAP risk-based, FY2020
$315.3M Sources
|
Recurring |
|
Behavioral & Specialty Health, ASO
Recurring
|
6.4% |
Behavioral & Specialty Health, ASO, FY2020
$291.6M Sources
|
Recurring |
|
PBM, including dispensing
Usage-based
10-K for FY2020, filed Feb 26, 2021 |
46% |
PBM, including dispensing, FY2020
$2.1B Sources
|
Usage-based |
|
Medicare Part D
Usage-based
|
5.3% |
Medicare Part D, FY2020
$243.7M Sources
|
Usage-based |
|
PBA
Recurring
|
3.0% |
PBA, FY2020
$136.2M Sources
|
Recurring |
|
Formulary management
Usage-based
|
2.3% |
Formulary management, FY2020
$104.9M Sources
|
Usage-based |
|
Other service lines
|
0.1% |
Other service lines, FY2020
$2.9M Sources
|
Health plans and managed-care organizations, employers, and government agencies contract for management services; care is delivered through provider networks, and pharmacy claims use Magellan’s contracted retail pharmacy network.
10-K for FY2020, filed Feb 26, 2021The Behavioral & Specialty Health reporting unit’s customers include health plans, accountable care organizations (“ACOs”), employers, the…View ↗
These services are available individually, in combination, or in a fully integrated manner. The Company markets its pharmacy management…View ↗
Magellan’s coordination and management of these healthcare and long-term support services are provided through its comprehensive network of…View ↗
The Company also has a national network of contracted retail pharmacies which is offered to its pharmacy benefit management customers. We…View ↗
Yes. It kept 8 cents of every revenue dollar as net income in FY2020 and turned 8 cents into free cash flow.
10-Q for Q3 FY2021, filed Nov 5, 2021
Open tableView ↗
8-K, filed Jan 4, 2022
At the effective time of the Merger (the “Effective Time”), pursuant to the Merger Agreement, each share of common stock, par value $0.01…View ↗
Held flat. Revenue was $4.6B in FY2020, about the same as the $4.8B of FY2016.
Sale of Medicaid care business
The business no longer includes MCC’s total-medical and long-term-support management for Medicaid and Medicare populations; Magellan sold that business and reports it as discontinued operations.
10-K for FY2017, filed Mar 1, 2018 10-K for FY2020, filed Feb 26, 2021The Government reporting unit contracts with local, state and federal governmental agencies to provide services to recipients under…View ↗
On December 31, 2020, we completed the sale of our Magellan Complete Care business (the “MCC Business”) to Molina Healthcare, Inc.…View ↗
The Healthcare segment (“Healthcare”) previously consisted of two reporting units – Behavioral & Specialty Health and Magellan Complete…View ↗
The MCC business, which is now reflected as discontinued operations, contracted with state Medicaid agencies and the Centers for Medicare…View ↗
Provider services
Healthcare moved beyond coordinating outside providers to include provider assets delivering primary and behavioral healthcare through an integrated approach.
10-K for FY2017, filed Mar 1, 2018 10-K for FY2020, filed Feb 26, 2021Magellan’s coordination and management of these healthcare and long term support services are provided through its comprehensive network of…View ↗
Medicare Part D exit
The older report marketed pharmacy services to Medicare Part D, while the latest report says Magellan planned to exit the Part D business but retain its employer group plan.
10-K for FY2017, filed Mar 1, 2018 10-K for FY2020, filed Feb 26, 2021These services are available individually, in combination, or in a fully integrated manner. The Company markets its pharmacy management…View ↗
On May 11, 2020, the Company announced its decision to exit the Medicare Part D business at the end of 2020. The Company will retain its…View ↗
Loading...
